๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

A randomized trial comparing mitoxantrone with doxorubicin in patients with stage IV breast cancer

โœ Scribed by Joseph C. Allegra; T. Woodcock; S. Woolf; I. C. Henderson; Shelley Bryan; A. Reisman; Gary Dukart

Publisher
Springer US
Year
1985
Tongue
English
Weight
529 KB
Volume
3
Category
Article
ISSN
0167-6997

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

A randomized trial of doxorubicin, mitox
A randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer (A South West Oncology Group Study)
โœ John D. Cowan; C. Kent Osborne; James A. Neidhart; Daniel D. Hoff; John J. Const ๐Ÿ“‚ Article ๐Ÿ“… 1985 ๐Ÿ› Springer US ๐ŸŒ English โš– 295 KB

New agents with increased activity and/or reduced toxicity are needed for the treatment of advanced breast cancer. The anthracene derivatives mitoxantrone and bisantrene had significant activity and acceptable toxicity in phase II trials. In an ongoing phasc III trial we have now randomized 150 pati

Randomized clinical trial comparing lapa
Randomized clinical trial comparing laparoscopic and open surgery in patients with rectal cancer
โœ J. Lujan; G. Valero; Q. Hernandez; A. Sanchez; M. D. Frutos; P. Parrilla ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 128 KB ๐Ÿ‘ 2 views

## Abstract ## Background The laparoscopic treatment of rectal cancer is controversial. This study compared surgical outcomes after laparoscopic and open approaches for mid and low rectal cancers. ## Methods Some 204 patients with mid and low rectal adenocarcinomas were allocated randomly to ope

Chronopharmacokinetics of doxorubicin in
Chronopharmacokinetics of doxorubicin in patients with breast cancer
โœ P. Canal; A. Sqalli; M. Forni; C. Chevreau; A. Pujol; R. Bugat; H. Roche; J. Ous ๐Ÿ“‚ Article ๐Ÿ“… 1991 ๐Ÿ› Springer ๐ŸŒ English โš– 543 KB

The chronopharmacokinetics of doxorubicin (DOX) has been studied in 18 patients suffering from breast cancer. They received combined chemotherapy including DOX (50 mg/m2 as an iv bolus), given at two different times (09.00 h or 21.00 h). The two randomized courses of the protocol were given to each